- Home
- EIC vs VNDA Comparison
EIC vs VNDA Comparison
Compare EIC & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- VNDA
- Stock Information
- Founded
- EIC N/A
- VNDA 2002
- Country
- EIC United States
- VNDA United States
- Employees
- EIC N/A
- VNDA N/A
- Industry
- EIC Finance/Investors Services
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- EIC Finance
- VNDA Health Care
- Exchange
- EIC Nasdaq
- VNDA Nasdaq
- Market Cap
- EIC 287.1M
- VNDA 282.8M
- IPO Year
- EIC 2019
- VNDA 2006
- Fundamental
- Price
- EIC $15.22
- VNDA $5.08
- Analyst Decision
- EIC Strong Buy
- VNDA Strong Buy
- Analyst Count
- EIC 1
- VNDA 2
- Target Price
- EIC $17.50
- VNDA $16.50
- AVG Volume (30 Days)
- EIC 262.3K
- VNDA 778.6K
- Earning Date
- EIC 02-20-2025
- VNDA 05-07-2025
- Dividend Yield
- EIC 15.75%
- VNDA N/A
- EPS Growth
- EIC N/A
- VNDA N/A
- EPS
- EIC 1.97
- VNDA N/A
- Revenue
- EIC $46,223,036.00
- VNDA $198,772,000.00
- Revenue This Year
- EIC $39.61
- VNDA $14.36
- Revenue Next Year
- EIC $27.28
- VNDA $44.53
- P/E Ratio
- EIC $7.75
- VNDA N/A
- Revenue Growth
- EIC 72.79
- VNDA 3.18
- 52 Week Low
- EIC $14.78
- VNDA $3.71
- 52 Week High
- EIC $16.75
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- EIC 36.60
- VNDA 58.96
- Support Level
- EIC $15.21
- VNDA $4.84
- Resistance Level
- EIC $16.05
- VNDA $5.07
- Average True Range (ATR)
- EIC 0.19
- VNDA 0.23
- MACD
- EIC -0.07
- VNDA 0.02
- Stochastic Oscillator
- EIC 10.71
- VNDA 70.63
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.